Endogenous Fungal Endophthalmitis following COVID-19 Hospitalization: Evidence from a Year-Long Observational Study.

PURPOSE: To describe cases of endogenous fungal endophthalmitis (EFE) post-recovery from or hospitalization for coronavirus disease 2019 (COVID-19). METHODS: This prospective audit involved patients with suspected endophthalmitis referred to a tertiary eye care center over a one-year period. Comprehensive ocular examinations, laboratory studies, and imaging were performed. Confirmed cases of EFE with a recent history of COVID-19 hospitalization±intensive care unit admission were identified, documented, managed, followed up, and described. RESULTS: Seven eyes of six patients were reported; 5/6 were male, and the mean age was 55. The mean duration of hospitalization for COVID-19 was approximately 28 days (14-45); the mean time from discharge to onset of visual symptoms was 22 days (0-35). All patients had underlying conditions (5/6 hypertension; 3/6 diabetes mellitus; 2/6 asthma) and had received dexamethasone and remdesivir during their COVID-related hospitalization. All presented with decreased vision, and 4/6 complained of floaters. Baseline visual acuity ranged from light perception (LP) to counting fingers (CF). The fundus was not visible in 3 out of 7 eyes; the other 4 had "creamy-white fluffy lesions" at the posterior pole as well as significant vitritis. Vitreous taps were positive for Candida species in six and Aspergillus species in one eye. Anti-fungal treatment included intravenous amphotericin B followed by oral voriconazole and intravitreal amphotericin B. Three eyes underwent vitrectomy; the systemic health of two patients precluded surgery. One patient (with aspergillosis) died; the others were followed for 7-10 months - the final visual outcome improved from CF to 20/200-20/50 in 4 eyes and worsened (hand motion to LP) or did not change (LP), in two others. CONCLUSION: Ophthalmologists should maintain a high index of clinical suspicion for EFE in cases with visual symptoms and a history of recent COVID-19 hospitalization and/or systemic corticosteroid use - even without other well-known risk factors.

Pharmacological therapy selection of type 2 diabetes based on the SWARA and modified MULTIMOORA methods under a fuzzy environment.

Medication selection for Type 2 Diabetes (T2D) is a challenging medical decision-making problem involving multiple medications that can be prescribed to control the patient's blood glucose. The wide range of hyperglycemia lowering agents with varying effects and various side effects makes the decision quite difficult. This paper presents computer-aided medical decision support using a fuzzy Multi-Criteria Decision-Making (MCDM) model that hybridizes a Step-wise Weight Assessment Ratio Analysis (SWARA) method with a modification of Fuzzy Multi-Objective Optimization on the basis of a Ratio Analysis plus the full multiplicative form (FMULTIMOORA) method for pharmacological therapy selection of T2D. It makes the use of SWARA for obtaining the relative significance of every selected criterion by soliciting experts' opinions and FMULTIMOORA method for evaluation of each alternative according to all criteria based on a published clinical guideline. In this paper, an extended reference point approach is considered in the proposed hybrid MCDM model that resolves the classic reference point limitations and improves the FMULTIMOORA ranking procedure. Computational results indicate that Metformin is confirmed as the first-line medication and Sulfonylurea as the second-line add-on therapy. The Glucagon-like peptide-1 receptor agonist, Dipeptidyl peptidase-4 inhibitor, and Insulin are placed 3rd, 4th, and 5th, respectively. A sensitivity analysis is conducted to validate the model performance by comparing its result with studies in the literature, other fuzzy MCDM techniques and an interval MULTIMOORA method based on an observational dataset. The close correspondence between the final rankings of anti-diabetic agents resulted from the proposed hybrid model and other methodologies provide significant implications for endocrinologists to refer.

Changes in growth hormone and insulin-like growth factor-I levels in the acute stage after open heart surgery and at the time of discharge.

INTRODUCTION: Stress conditions are known to disturb the axis of growth hormone (GH)/insulin-like growth factor-I (IGF-I), but there is little data on this topic after open heart surgery. This study aimed to investigate changes in GH/IGF-I axis in adults undergoing open heart surgery. METHODS: A total of 162 adult patients admitted for elective major cardiac surgery were studied in a prospective setting. Serum concentrations of GH and IGF-I were measured at four time points: before operation as a baseline, 4 and 12 hours after operation in ICU, and at the time of discharge. Two to 4 venous blood samples were obtained from each patient. To study the changes of GH and IGF-I levels over time, general linear model for repeated measures was applied. RESULTS: Mean age of patients was 51.2+/-14.3 years. Compared with preoperative values (median 0.8, range 0.05-19.4 ng/mL), GH levels rose significantly at four (median 3.3, range 0.1-55 ng/mL) and twelve hours after surgery (median 5.45, range 0.55-61.2 ng/mL), and continued to remain high at the time of discharge (median 2.1, range 0.02-22.7 ng/mL) (p<0.05). Conversely, compared with preoperative levels (173.5+/-89.9 ng/mL), IGF-I decreased at four (140.9+/-66.9 ng/mL) and twelve hours after operation (135.9+/-59.9 ng/mL) and reached its nadir on the day of discharge (114.8+/-43.8 ng/mL) (p<0.01). The patterns of changes in GH and IGF-I over time were significantly different (p<0.01). CONCLUSION: Adult patients undergoing open heart surgery go through a state of GH resistance characterized by elevated GH and decreased IGF-I levels from the initial hours after operation.

Identification of peptides specific for antibodies in vitiligo using a phage library.

Patients with vitiligo produce specific autoantibodies that can be detected in their sera. These antibodies are believed to play a role in the pathogenesis of this disease. A random peptide library displayed on phage is a technique that can be used to identify the epitopes that react with monoclonal and polyclonal antibodies. We used this technique to identify the epitopes that react specifically with the vitiligo autoantibodies. By screening the random peptide phage library and using ELISA, two clones that showed a higher frequency of reactivity with the antibodies in the sera of patients with vitiligo were identified. The peptides do not show any similarity with the autoantigens so far implicated in vitiligo, indicating that these epitopes may mimic conformational epitopes in proteins.

Treatment of goitrous hypothyroidism with iodized oil supplementation in an area of iodine deficiency.

In order to investigate the effect of iodized oil administration on the thyroid status of male hypothyroid children and adolescents residing in an area of iodine deficiency, 32 apparently normal school boys with increased serum TSH, aged 7 to 15 years, were given a single intramuscular injection of 480 mg iodized oil. Four months after injection, serum T4 increased from 60 +/- 23 to 118 +/- 24 nmol/l and serum TSH decreased from 39 +/- 33 to 2.5 +/- 1.2 mU/l. Serum T4 remained unchanged while a further decline in TSH to 1.3 +/- 0.9 and 1.4 +/- 1.3 mU/l was observed 7 and 12 months after injection, respectively. There was a small but significant reduction in serum T3, FT3I as well as in the prevalence and severity of goiter 1 year following iodine treatment. Neither the age of the subject nor the severity of hypothyroidism affected the thyroid response to iodine treatment. It is concluded that iodized oil injection is an effective and convenient treatment for goitrous hypothyroid youngsters in iodine deficient areas.